Literature DB >> 7630167

Tumor necrosis factor alpha stimulates gluconeogenesis from alanine in vivo.

D Blumberg1, S Hochwald, M Burt, D Donner, M F Brennan.   

Abstract

An increase in gluconeogenesis contributes to the cachexia seen in severe injury, sepsis, and malignancy by converting amino acids from skeletal muscle to glucose. Since tumor necrosis factor alpha (TNF alpha) may mediate this cachexia, we examined the effect of this cytokine on gluconeogenesis. Twenty-eight male Fischer rats were injected intraperitoneally with TNF alpha (250 micrograms/kg) or saline, and after 4 hours, isolated hepatocytes were obtained by in situ collagenase liver perfusion. Hepatocytes were incubated with alanine (10 mM), and rates of gluconeogenesis were determined. Plasma lactate, glucose, insulin, glucagon, cortisol, and amino acids were measured. TNF alpha administration resulted in a 50% increase in gluconeogenesis from alanine (P < 0.05) and a three-fold increase in plasma glucagon (P = 0.01). Total and glucogenic plasma amino acids decreased with TNF alpha injection (P < 0.05). In vivo TNF alpha causes an increase in hepatic gluconeogenesis associated with increased plasma glucagon.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7630167     DOI: 10.1002/jso.2930590404

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  Glucocorticoid-dependent induction of interleukin-6 receptor expression in human hepatocytes facilitates interleukin-6 stimulation of amino acid transport.

Authors:  C P Fischer; B P Bode; K Takahashi; K K Tanabe; W W Souba
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

Review 2.  Stress hyperglycaemia.

Authors:  Kathleen M Dungan; Susan S Braithwaite; Jean-Charles Preiser
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

Review 3.  Management of critically ill patients with type 2 diabetes: The need for personalised therapy.

Authors:  Palash Kar; Karen L Jones; Michael Horowitz; Adam M Deane
Journal:  World J Diabetes       Date:  2015-06-10

Review 4.  Glycemic control in the medical intensive care unit.

Authors:  Michelle A Kovalaske; Gunjan Y Gandhi
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

5.  A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.

Authors:  Dongquan Huang; Jie Gao; Chong Li; Caihong Nong; Wenting Huang; Xifen Zheng; Sirou Li; Yongzheng Peng
Journal:  Psychopharmacology (Berl)       Date:  2021-05-27       Impact factor: 4.530

6.  Inhibitory effect of tumor necrosis factor α on gluconeogenesis in perfused rat liver.

Authors:  Aline Franco da Rocha; Thaís Fernanda Liboni; Carolina Campos Lima Moreira; Daniele Romani Miksza; Camila Oliveira de Souza; Flaviane de Fatima Silva; Glaucia Regina Borba-Murad; Roberto Barbosa Bazotte; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2012-12-09       Impact factor: 3.396

Review 7.  Glycemic control in critically ill patients.

Authors:  Chien-Wei Hsu
Journal:  World J Crit Care Med       Date:  2012-02-04

Review 8.  Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms.

Authors:  Mingmin Li; Guo Chen; Yingqing Feng; Xuyu He
Journal:  Front Cardiovasc Med       Date:  2021-05-12

9.  LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.

Authors:  Muhammad Anas Kamleh; Stuart G Snowden; Dmitry Grapov; Gavin J Blackburn; David G Watson; Ning Xu; Mona Ståhle; Craig E Wheelock
Journal:  J Proteome Res       Date:  2014-11-12       Impact factor: 4.466

10.  Lipopolysaccharide inhibits hepatic gluconeogenesis in rats: The role of immune cells.

Authors:  Hiroshi Tanaka; Yoshikazu Nishikawa; Toru Fukushima; Ataru Taniguchi; Yoshihito Fujita; Kinsuke Tsuda; Nobuya Inagaki; Masaya Hosokawa
Journal:  J Diabetes Investig       Date:  2017-08-14       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.